Preimplantation Genetic Testing Market to Hit US$552.7 Million in 2025, Says Persistence Market Research

The preimplantation genetic testing (PGT) market is witnessing steady growth, driven by a rising prevalence of genetic disorders and increasing adoption of in vitro fertilization (IVF) procedures worldwide. According to Persistence Market Research, the global market is projected to reach a value of US$552.7 million in 2025, with an anticipated growth to US$999.2 million by 2032 at a CAGR of 8.8%. This growth is fueled by technological innovations, including next-generation sequencing (NGS) and advanced embryo biopsy techniques that have significantly improved test accuracy and clinical reliability.

The growing awareness among prospective parents regarding hereditary diseases, coupled with the trend of delayed parenthood, is also a key driver. Fertility clinics are increasingly integrating genetic testing as part of assisted reproductive technologies (ART), ensuring higher success rates in embryo implantation. The availability of user-friendly PGT kits and automated platforms is streamlining workflows in fertility centers, enhancing both accessibility and efficiency for patients seeking IVF treatments.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34757

Market Statistics and Key Growth Drivers

The PGT market is being propelled by multiple factors. The expansion of ART procedures is a prominent growth driver. As the number of ART cycles rises globally, preimplantation genetic testing provides clinicians with a mechanism to select embryos with normal chromosomal structures, thereby reducing the risk of miscarriage and ensuring healthier pregnancies. Persistence Market Research highlights that in the U.S., the number of ART cycles increased from 326,468 in 2020 to 435,426 in 2022, reflecting the growing demand for integrated PGT procedures.

Technological advancements such as non-invasive PGT, AI-based embryo viability assessment, and NGS-driven chromosomal analysis are providing new avenues for precise embryo selection. Increasing maternal age, growing awareness of genetic disorders, and supportive government regulations, especially in developed markets, are further driving the market forward. The convenience, accuracy, and efficiency provided by automated testing solutions have made PGT an indispensable component of fertility treatments.

Leading Segment and Geographical Region

Within the PGT market, the aneuploidy application segment has emerged as the leading category, accounting for a substantial 41% revenue share in 2024. This dominance is primarily attributed to the high prevalence of chromosomal abnormalities, particularly among women of advanced maternal age, and the critical role of PGT-A in improving IVF success rates. Advances in next-generation sequencing and rising awareness of genetic screening benefits have further fueled the adoption of aneuploidy testing globally.

Geographically, North America dominates the preimplantation genetic testing market. The region's leadership is driven by widespread adoption of ART, strong healthcare infrastructure, and substantial investment in genetic research. In addition, favorable reimbursement policies and technological advancements in fertility clinics have made genetic screening more accessible. Rising maternal age, a higher prevalence of hereditary disorders, and active collaborations between academic institutions and diagnostic companies also support North America's position as a global market leader.

Key Highlights from the Report

• Rising infertility rates and delayed childbearing cater to the market's growth.
• High-end developments in genetic testing technology are driving the market forward.
• Integration of personalized medicine and precision presents an opportunity for the market players.
• Increasing awareness about genetic disorders is fueling the adoption of PGT.
• Advanced fertility treatments and supportive regulatory frameworks enhance market expansion.
• North America leads due to technological advancements and strong healthcare infrastructure.

Market Segmentation

The PGT market is segmented based on product type, application, and end-user, offering a comprehensive view of growth areas. Among product types, kits dominate due to their ability to standardize testing workflows and simplify clinical operations. These kits are designed with pre-validated reagents and optimized protocols, minimizing human error and making genetic testing accessible even in emerging healthcare markets. Automated platforms complement kits by streamlining workflow in IVF clinics, thereby enhancing efficiency and reducing costs.

Application-based segmentation indicates that aneuploidy testing is the fastest-growing segment, primarily due to the increasing prevalence of chromosomal abnormalities and the need to avoid implantation failure and miscarriage. Other applications, such as monogenic disorder testing and structural rearrangement screening, are also contributing to market growth by offering specialized diagnostic solutions. End-users of PGT include fertility clinics, hospitals, and diagnostic laboratories, each leveraging advanced technologies to deliver accurate testing and improved patient outcomes.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/preimplantation-genetic-testing-market.asp

Regional Insights

North America continues to lead the global PGT market, particularly in the U.S., due to extensive use of advanced reproductive technologies and high patient awareness of genetic screening. The presence of leading diagnostic companies and fertility clinics, coupled with strong regulatory support and favorable reimbursement policies, drives market expansion.

Europe is showing consistent growth, with countries like the United Kingdom projected to record the highest CAGR from 2025 to 2032. Adoption of IVF and increasing awareness of hereditary disorders, along with robust genetic research infrastructure, are key factors enhancing the market in the region. Meanwhile, Asia Pacific offers significant growth potential due to rising awareness of fertility care, improvements in healthcare infrastructure, and increasing adoption of assisted reproductive technologies in countries like China, India, and Japan.

Market Drivers

The primary driver of the preimplantation genetic testing market is the expanding use of assisted reproductive technologies (ART). With the increasing number of couples seeking fertility solutions, integrating PGT into ART procedures helps ensure the selection of healthy embryos, reducing the risk of genetic disorders and improving pregnancy success rates. Advanced technologies, such as NGS and AI-based embryo assessment, further enhance the effectiveness of these procedures.

Market Restraints

Despite its benefits, the PGT market faces challenges that limit widespread adoption. One major restraint is the risk of embryo damage during the biopsy process, which can potentially compromise pregnancy outcomes. Diagnostic inaccuracies, mosaicism, and ethical concerns surrounding embryo selection also hinder trust in these procedures. Legal challenges, as seen in Australia's Monash IVF case, emphasize the need for improved clinical oversight and patient counseling, which may slow market growth.

Market Opportunities

Technological advancements in genetic testing present significant opportunities for the PGT market. Innovations such as non-invasive PGT, AI-assisted embryo selection, and high-resolution chromosomal analysis enable safer and more accurate procedures. Integration of AI and NGS in IVF clinics has improved pregnancy and live birth rates while minimizing risks associated with traditional biopsy methods. These developments provide a pathway for broader adoption, especially in emerging markets where access to advanced fertility care is increasing.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34757

Reasons to Buy the Report

• Comprehensive analysis of market trends and growth drivers for strategic decision-making.
• Detailed insights into market segmentation, including product type, application, and end-user.
• Thorough regional insights, highlighting North America, Europe, and Asia Pacific growth potential.
• Competitive landscape evaluation, including key players and recent technological developments.
• Actionable intelligence for investment planning, business expansion, and market entry strategies.

Frequently Asked Questions (FAQs)

• How Big is the Preimplantation Genetic Testing Market?
• Who are the Key Players in the Global Market for Preimplantation Genetic Testing?
• What is the Projected Growth Rate of the Preimplantation Genetic Testing Market?
• What is the Market Forecast for Preimplantation Genetic Testing for 2032?
• Which Region is Estimated to Dominate the Industry through the Forecast Period?

Company Insights

The PGT market features a dynamic competitive landscape, comprising both established companies and emerging biotech firms. Key players include:

• Thermo Fisher Scientific, Inc.
• COOPER SURGICAL, INC.
• Illumina, Inc.
• Abbott
• Agilent Technologies, Inc.
• Medicover Genetics
• Revvity Inc
• Takara Bio Inc.
• Genea BIOMEDX
• SeraCare Life Sciences
• Shiva Scientific Company

Recent Developments

• In January 2025, Illumina, Inc. launched major upgrades to its NovaSeq X Series, including a single-flow-cell system and enhanced software to improve sequencing efficiency.
• In September 2024, CooperSurgical introduced an FDA-approved single-hand-use inserter for Paragard®, streamlining fertility-related procedures and improving user experience.

Conclusion

The preimplantation genetic testing market is poised for substantial growth, driven by advancements in reproductive technologies, increasing awareness of genetic disorders, and technological innovations such as NGS and AI-assisted embryo analysis. North America leads the market, followed by Europe and the Asia Pacific region, offering significant expansion potential.

Despite challenges related to embryo damage, ethical concerns, and diagnostic inaccuracies, the integration of non-invasive testing and AI-driven solutions is paving the way for safer, more efficient, and accessible PGT services. Fertility clinics and diagnostic companies continue to focus on innovation, automation, and patient-centric solutions, ensuring that the PGT market remains a critical component of modern reproductive healthcare. With projected growth to nearly US$999.2 million by 2032, stakeholders in the industry are well-positioned to capitalize on the expanding demand for personalized fertility solutions and precision genetic testing.

Read More Related Reports:

Preclinical Pet Spect Ct Systems Market https://www.persistencemarketresearch.com/market-research/preclinical-pet-spect-ct-systems-market.asp
Gastric Electric Stimulators Market https://www.persistencemarketresearch.com/market-research/gastric-electric-stimulators-market.asp
Small Joint Replacement Market https://www.persistencemarketresearch.com/market-research/small-joint-replacement-market.asp
Neurovascular Embolization Devices Market https://www.persistencemarketresearch.com/market-research/neurovascular-embolization-devices-market.asp
Injectable Nanomedicines Market https://www.persistencemarketresearch.com/market-research/injectable-nanomedicines-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.